00:00It is a very important thing to know about HIV.
00:02This is why we are making a pill for HIV.
00:09Since one week, we are making a pill for HIV.
00:16We are making a pill for HIV.
00:18We are making a pill for HIV.
00:20We are making a pill for HIV.
00:23in the UDDA system and as well as in the worked system and in bronvenation, we have
00:27available these four vaccines, but UNDVA is very important, they give you know, and
00:34they give them ARV and UNDVA also in the colds of the well-being, and in cat 3 our UNDVA
00:38is
00:38available as the standard vaccines for the UNDVA they give you the Provision.
00:43There are multiple scratch mats, a violent dog cut into the body, a receded principle,
00:49So, there is a lot of damage and contamination in that case, with ARV and ARS, so that ARS trend
00:56and A&M, which is inflated by putting it into place.
01:00That's why we are ensuring that there are more cases of mapping.
01:06We don't have active treatment, passive treatment.
01:09this is a very nice thing.
01:15So, whoever is here,
01:16whoever is here,
01:17whoever is here,
01:17whoever is here,
01:18I will say that
01:20the two treatments will be used.
01:24Because when we have the passive treatment,
01:27what is the result of the virus?
01:29We have the virus that is in place.
01:31We have the virus that is in place.
01:32But we have the virus that is in place.
01:35We have the virus that is in place.
01:42foreign
01:48foreign
02:36Thank you very much.
02:37togetherness
02:38which is a team
02:40that we have
02:42combinedly
02:42and
02:43and
02:44and
02:45and
02:47and
02:48and
02:48and
02:48and
02:49and
